Table 1 Patient demographics and characteristics at baseline
Characteristic | ITT population (n = 2004) |
|---|---|
Age (years) | |
 Median age | 59 |
 Range | 19–85 |
Gender, n (%) | |
 Male | 1438 (72%) |
 Female | 566 (28%) |
ECOG performance status, n (%) | |
 0 | 309 (15%) |
 1 | 1379 (69%) |
 2 | 308 (15%) |
 3 | 2 (< 1%) |
Unknown | 6 (< 1%) |
Stage, n (%) | |
 III | 70 (3%) |
 IV | 1931 (96%) |
 Unknown | 3 (< 1%) |
Extra-gastric metastases, n (%) | |
 Yes | 1979 (99%) |
 No | 22 (1%) |
 Unknown | 3 (< 1%) |
Number of metastatic sites, n (%) | |
  ≤ 2 | 1293 (65%) |
  > 2 | 686 (34%) |
Prior lines of chemotherapy, n (%) | |
  ≤ 2 | 1514 (76%) |
  > 2 | 486 (24%) |
Unknown | 4 (< 1%) |
Prior gastrectomy, n (%) | |
 Yes | 1491 (74%) |
 No | 510 (25%) |
 Unknown | 3 (< 1%) |
Previous systemic anticancer agents | |
 Fluoropyrimidine | 1976 (97%) |
 Platinum | 1884 (94%) |
 Taxane | 1554 (78%) |
 Irinotecan | 542 (27%) |
 Anthracyclines | 125 (6%) |
 Anti-HER2 therapy | 75 (4%) |
 Ramucirumab | 9 (< 1%) |
 Immunotherapy (anti-PD-1 or anti-CTLA-4) | 5 (< 1%) |
 Other | 266 (13%) |